OcuPharma: A commitment to innovation and ophthalmology
OcuPharma applies the most stringent FDA standards to formulate TMoxiOG™ and our topical formulations, preparing for FDA approval while satisfying the 503b surgical end-user, a meticulous process that redefines compounding excellence.
Creating innovative ophthalmic formulations for eye doctors
Our comprehensive suite of preservative-free ophthalmic medications caters to the diverse preferences of eye surgeons and optometrists, ranging from injectable prophylaxis after cataract surgery to potent preservative-free steroid-antibiotic combination eye drops.
Seeking FDA Approval: TMoxiOG
Pursuing a drop-free solution with cataract surgery is a universal goal for surgeons and patients.
Serving the USA Market First
503b manufacturing with the CMO quality assurance process to satisfy FDA 505b2 approval
Introducing Topical DuraMoxi™
Difluprednate, the active ingredient in Durezol™, combined with Moxifloxacin
Global Patent Protection
The only combination formulation patented in Europe, North America, South America, and Asia
Rapidly Growing Surgical Market
10% of the 3.5M cataracts (USA) annually. Once FDA approved: 60% market with ASC reimbursement (J-Code).
International Sales Planned
FDA approval of TMoxiOG will be followed by International approvals: 85M cataracts annually
503b Production CMO Manufacturing
Best cGMP manufacturing to FDA standards for approved medications, highest quality and safety, rigorous validation and surveillance
TMoxiOG™ Injectable
- ASC/HOPD Vials (0.6ml)
- Bulk Purchases in boxes of 20
- Just in Time Delivery Promise
- Once FDA Approved: Reimbursable
DuraMoxi™ Topical
- Potent steroid; 4th Generation Antibiotic
- Twice a day (BID) Suppression Dosing
- Preservative-Free, No Irritation
- Submicron-Size Particles: No Clumping
“TMoxiOG™ has been used in nearly two million eyes with excellent prophylaxis results, saving patients with perfect compliance and incredible convenience.”
Jeffrey Liegner, MD
CEO, OcuPharma
Watch, Read, Listen, Share, Blog
-
Hello Eye Surgeons and Optometrists! Ask for the OG for the patient’s benefit.
Your patients deserve the original triamcinolone-moxifloxacin formulation with a patented formulation, preparing to seek FDA approval, followed by J-Code assignment, leading to ASC/HOPD reimbursement by insurance and Medicare, saving our US Government (Medicare Part D) over $7B in the first decade.
Join 900+ eye surgeons having used TMoxiOG™
Stay in the loop with drop-free surgical prophylaxis.